|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...162163164165166167168169170171172...10651066» |
- Ninlaro (ixazomib) / Takeda
IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6 () - May 12, 2023 - Abstract #EHA2023EHA_2989;
P4
The expecteddecrement in outcomes associated with older age/frailty was not observed. Long-term triplet consolidation with ixazomib-Rd may provide an alternative approach to induction/maintenance in the community for pts with comorbidities and/or frailty who are not eligible for upfront transplantation.
- ABBV-383 / AbbVie
ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION () - May 12, 2023 - Abstract #EHA2023EHA_2988;
P1
Efficacy endpoints include ORR, PFS, DOR, time to progression and minimal residual disease negativity. Summary/
- bortezomib / Generic mfg., dexamethasone / Generic mfg., pomalidomide / Generic mfg.
BORTEZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH RELAPSE AND REFRACTORY AL AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE () - May 12, 2023 - Abstract #EHA2023EHA_2986;
BPd is well tolerated with few side effects and warrants continued investigation as a treatment for AL amyloidosis. Amyloidosis
- Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION () - May 12, 2023 - Abstract #EHA2023EHA_2975;
P2
But the initial 6 patients (XPD-60) experienced more frequent dose interruptions and/or dose reductions than patients in XPD -40 group and these patients mentioned that the adverse events of nausea and fatigue had an obviously bad influence on their quality of life even though they were mainly grade 1 or 2. This study suggests that XPD-40 regimen may be more feasible in clinical practice with comparable effectiveness and fewer adverse events which needs further exploration.
- Empliciti (elotuzumab) / AbbVie, BMS, linvoseltamab (REGN5458) / Regeneron
TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) () - May 12, 2023 - Abstract #EHA2023EHA_2971;
P3
This study suggests that XPD-40 regimen may be more feasible in clinical practice with comparable effectiveness and fewer adverse events which needs further exploration. Eligible patients will have received 1
- elranatamab (PF-06863135) / Pfizer, Darzalex (daratumumab) / J&J
MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA () - May 12, 2023 - Abstract #EHA2023EHA_2969;
P2, P3
Eligible patients will have received 1 N/A Multiple myeloma, Bispecific, Clinical trial, B-cell maturation antigen
- Darzalex (daratumumab) / J&J
CLINICAL CONSENSUS ON FIRST-LINE (1L) TREATMENTS FOR TRANSPLANT- INELIGIBLE (TIE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): DELPHI PANEL OF US HEMATOLOGISTS AND ONCOLOGISTS () - May 12, 2023 - Abstract #EHA2023EHA_2967;
DRd or D-containing quad regimens were considered by most as the most efficacious 1L therapy for TIE NDMM. These data may aid physician decision making in the absence of head-to-head trials among current triplet and quad regimens.
- ZN-d5 / Zentalis Pharma
A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS () - May 12, 2023 - Abstract #EHA2023EHA_2961;
P1/2
Dose escalation cohorts arecurrently undergoing evaluation and the study is open to enrollment. Upon determination of the RP2D, the study will commence Phase 2.
- Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD) () - May 12, 2023 - Abstract #EHA2023EHA_2951;
P1b/2
It is worthy of further study based on the preliminary efficacy results. Long-term results still require more patients to be enrolled and further follow-up.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., thalidomide / Generic mfg.
EPIDEMIOLOGICAL DESCRIPTION AND PROGNOSIS FEATURES OF MULTIPLE MYELOMA IN A TUNISIAN HAEMATOLOGY CENTER () - May 12, 2023 - Abstract #EHA2023EHA_2948;
It also identified the main prognostic factors that should be includedin the initial assessment to improve medical management and to ensure high survival rates. Plasma cells, Multiple myeloma, Monoclonal gammopathy, Autograft
- Darzalex (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID- 19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS () - May 12, 2023 - Abstract #EHA2023EHA_2881;
However, all the infections were mild and did not impact the response to anti-MM therapy. Further analysis may help develop a risk-stratified approach to prevention measures and assess the role of IV Ig in the winter period Infection, Multiple myeloma
- Adcetris (brentuximab vedotin) / Seagen, Takeda
TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED / REFRACTORY HODGKIN LYMPHOMA. () - May 12, 2023 - Abstract #EHA2023EHA_2853;
Given the small number of courses more data are needed to confirm these results. Hodgkin's lymphoma, Chemotherapy toxicity, Hematotoxicity
- hydrocortisone / Generic mfg., etoposide IV / Generic mfg.
ATAXIA LEADING TO A DIAGNOSIS OF PEDIATRIC CNS-ISOLATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN GRISCELLI SYNDROME TYPE 2 () - May 12, 2023 - Abstract #EHA2023EHA_2839;
This case highlights the need for early consideration of immunologic and genetic evaluation for HLH and GS2 in patients with unexplained neuro-inflammation, especially in the presence of partial albinism. Hemophagocytic Lymphohistiocytosis (HLH)
- dexamethasone / Generic mfg., etoposide IV / Generic mfg.
SECONDARY HLH: RETROSPECTIVE DATA FROM TERTIARY CARE CENTRE. () - May 12, 2023 - Abstract #EHA2023EHA_2837;
Treatment is often postponed due to delayed recognition of this deadly disease. A high degree of medical suspicion in the appropriate clinical context should prompt early treatment with an Dexamethazone and Etoposide-containing regimen.
- Yescarta (axicabtagene ciloleucel) / Gilead
ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING () - May 12, 2023 - Abstract #EHA2023EHA_2748;
P2
A high degree of medical suspicion in the appropriate clinical context should prompt early treatment with an Dexamethazone and Etoposide-containing regimen. ZUMA-1 Cohort 6, which evaluated whether improved safety outcomes were observed with prophylactic corticosteroids and earlier use of corticosteroids and/or tocilizumab to manage CRS and NEs, demonstrated no Grade ?3 CRS and 18% Grade ?3 NEs with high, durable response rates (ORR, 95%; CR rate, 80%) after ?2 years median follow-up (Oluwole et al...Patients will undergo leukapheresis, followed by lymphodepleting chemotherapy (fludarabine/cyclophosphamide) and a single axi-cel infusion (2
- Imbruvica (ibrutinib) / AbbVie, J&J
PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA () - May 12, 2023 - Abstract #EHA2023EHA_2724;
P2
Among ten patients who received ibrutinib previously, one and three achieved CMR and PMR, respectively. VAD shows promising clinical efficacy in patients with relapsed or refractory MCL with manageable and predictable toxicity (BATMAN ClinicalTrials.gov number, NCT02840539).
- EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMA, NASAL-TYPE : ABOUT 11 CASES () - May 12, 2023 - Abstract #EHA2023EHA_2717;
However, the prognosis of this disease remains poor and its evolution is difficult to predict, especially in the absence of the patient's immune status towards EBV and the viral load monitoring. NK-T cells, Non-Hodgkin's lymphoma, Extranodal lymphoma
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
OUTCOMES OF PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL) WHO UNDERWENT TREATMENT WITH DEANGELIS, MATRIX, AND PRIMAIN PROTOCOL.: A RETROSPECTIVE SINGLE-CENTER STUDY () - May 12, 2023 - Abstract #EHA2023EHA_2709;
The MATRix protocol demonstrated better clinical outcomes compared to DeAngelis and RMP. Compounding factors including age, perfromanace status and associated co-morbidities also influenced the outcome.
- Vesanoid (tretinoin) / Roche
NOT ALL VARIANTS OF ACUTE PROMYELOCYTIC LEUKEMIAS ARE RESISTANT TO RETINOIDS. () - May 12, 2023 - Abstract #EHA2023EHA_2677;
Compounding factors including age, perfromanace status and associated co-morbidities also influenced the outcome. He was found to have persistent leukocytosis despite treatment with IV ampicillin
- dexamethasone / Generic mfg., idarubicin hydrochloride / Generic mfg.
ACQUIRED FACTOR VII DEFICIENCY ASSOCIATED WITH ACUTE MYELOID LEUKEMIA () - May 12, 2023 - Abstract #EHA2023EHA_2610;
Steroids have shown promising results that we can't assess. The FVII deficiency, which spontaneously cleared after induction chemotherapy and with the disappearance of blasts, must motivate to discuss a possible link between factor VII deficiency and myeloid blasts.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA. () - May 12, 2023 - Abstract #EHA2023EHA_2520;
70 4 (57) Performance status 1 . 1 4 (57) 2 3 (43) WBC (x 10 9 / L) 10.7 (5.1-13.3) BCR-ABL transcript p190 5 (72) p210 1 (14) p190 + p210 1 (14) Baseline CV risk factors Hypertension 2 (28.5) Diabetes 2 (28.5) Dyslipidaimia 3 (43) Coronary artery disease 1 (14) Chemotherapy Hyper-CVAD 4 (57) Non-intensive chemo 3 (43) ALL, Philadelphia chromosome
- Darzalex (daratumumab) / J&J, iberdomide (CC-220) / BMS
EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA () - May 12, 2023 - Abstract #EHA2023EHA_2500;
P3
1 4 (57) 2 3 (43) WBC (x 10 9 / L) 10.7 (5.1-13.3) BCR-ABL transcript p190 5 (72) p210 1 (14) p190 + p210 1 (14) Baseline CV risk factors Hypertension 2 (28.5) Diabetes 2 (28.5) Dyslipidaimia 3 (43) Coronary artery disease 1 (14) Chemotherapy Hyper-CVAD 4 (57) Non-intensive chemo 3 (43) ALL, Philadelphia chromosome This phase 3 study will provide valuable insight into the efficacy and safety of IberDd as a potential treatment for patients with RRMM.
- Darzalex (daratumumab) / J&J
QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL (festival hall) - May 12, 2023 - Abstract #EHA2023EHA_2475;
Management of ultra-high-risk MM (2+ HRCA) remains an unmet medical need even in the context of quadruplet therapy and these patients maybe candidates for early deployment ofstrategies including T-cell redirection. Monoclonal antibody, Myeloma, Minimal residual disease (MRD)
- Blenrep (belantamab mafodotin) / GSK
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3) (Hall Boiron) - May 12, 2023 - Abstract #EHA2023EHA_2412;
P2, P3
However, median PFS was longer for belamaf monotherapy and belamaf induced deeper, more durable responses than Pd. No new safety signals were observed.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL (Harmony 2) - May 12, 2023 - Abstract #EHA2023EHA_2397;
These variations of the treatment schedule reduced the incidence of SOS compared with the original design. Relapsed acute lymphoblastic leukemia, Survival, Acute lymphoblastic leukemia, Phase II
- OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2151;
Relapsed acute lymphoblastic leukemia, Survival, Acute lymphoblastic leukemia, Phase II 10 qualified subjects with R/R AML aged between 18 and 65 years-old were enrolled and received round(s) of infusion of anti-CD33 CAR NK cells (6
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Actemra IV (tocilizumab) / Roche, JW Pharma
POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2147;
P1/2
CD-19 CAR T cells administration for AML is feasible and safe. However, the response is short and should be followed by a second transplant or alternative anti leukemic therapies.
- Darzalex (daratumumab) / J&J
HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2064;
P4
Frail pts showed poor HRQoL improvements over time, as compared with fit and intermediate-fit pts. Multiple myeloma, Real world data, Quality of life, Bortezomib
- Jakafi (ruxolitinib) / Novartis, Incyte, Darzalex (daratumumab) / J&J, Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
HERPES ZOSTER VACCINATION IN HEMATOLOGY. A SINGLE CENTER EXPERIENCE. (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1954;
Although the number of patients with post- vaccine HZ was very small, we observed that infection was much milder, lasted less and was devoid of subsequent complications. Infection, Vaccination, Herpesvirus
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
EFFECTS OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSA) FOR PRIMARY GRAFT FAILURE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA MAJOR (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1625;
Post-transplant testing and treatment for patients with DSA are crucial for successful engraftment. GR occurs more likely in the condition of median or higher DSA(MFI > 5000), under which the CD34 counts (10 6 /kg) of the transfusion dosage of donor cells reach above 20 is recommended.
- ondansetron / Generic mfg.
NEPA VERSUS ONDANSETRON FOR THE PREVENTION OF CINV IN PATIENTS WITH MULTIPLE MYELOMA OR LYMPHOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. A MONOCENTRIC REAL-LIFE EXPERIENCE. (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1601;
Given the highburden of CINV in the whole population analyzed in the study, regardless of the antiemetic used, it would be useful to identify patients at greatest risk and standardize CINV prophylaxis and treatment protocols depending on the different chemotherapy regimens and their emetogenic risk. Myeloma, Lymphoma, CINV prophylaxis, Autologous hematopoietic stem cell transplantation
- Blincyto (blinatumomab) / Astellas, Amgen
INNOVATIVE REDUCED-DOSE CHEMOTHERAPY FOLLOWED BY BLINATUMOMAB INDUCTION THERAPY FOR SUCCESSFUL MANAGEMENT OF TREATMENT NAIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ADULTS: A MULTICENTER, REAL-WORLD STUDY (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1503;
Thisstudy successfully explored the dose balance between chemotherapy and blinatumomab, which could help improve survival outcomes and limit chemotherapy-related toxicity in B-ALL. Real world data, Induction chemotherapy, B cell acute lymphoblastic leukemia
- dexamethasone / Generic mfg.
COMPARISON OF MORPHOLOGICAL & MRD RESPONSE WITH DEXAMETHASONE VERSUS PREDNISOLONE IN BFM 2009 INDUCTION THERAPY IN PEDIATRIC AND AYA ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER STUDY FROM INDIA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1500;
Multiple studies showed dexamethasone (Dexa) had superior response than prednisone (Pred) in high-risk ALL & had decreased cumulative relapse, but at the cost of increased toxicity. In our single-centre experience, use of dexamethasone in induction phase of ALL BFM 2009 regimen in pediatric & adolescent ALL was associated with achievement of significantly higher post-induction complete remission rate compared to prednisolone, without significant differences in day 15 & day 33 Flow-MRD responses, & overall treatment-related adverse events in the two steroid groups.
- Blincyto (blinatumomab) / Astellas, Amgen
SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH- B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1498;
Responses appeared durable with this lower intensity treatment approach despite a low rate of allogeneic stem cell transplantation and the exclusion of anthracyclines and asparaginase from treatment. Despite failing to meet proof-of-concept criteria the EFS and OS were encouragingfor older ALL patients and demonstrates the feasibility of combining low-intensity chemotherapy with blinatumomab in older adults with BCP-ALL.
- WU CART 007 / Wugen, Actemra IV (tocilizumab) / Roche, JW Pharma
PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL) (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1485;
P1/2
in a subset of patients. This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL.
- dexamethasone / Generic mfg., etoposide IV / Generic mfg.
NOVEL METHODS FOR THE IDENTIFICATION OF A RARE DISEASE, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1408;
Our expanded algorithm captured a substantial number of patients that would have been missed with identification using ICD codes alone, indicating a potential underestimation of HLH incidence. Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS)
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1376;
P2
Dose reduction of chemotherapy after CMR achievement decreased toxicity and did not have impact on outcome.Funding : Supported in part by the grant 2021 SGR 00771, AGAUR, Generalitat de Catalunya, Spain. Figure 1 .
- Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1239;
P2
Figure 1 . Eligible pts had newly diagnosed MM (NDMM), received ?3 cycles of induction therapy (tx; including a proteasome inhibitor, immunomodulatory agent, and dexamethasone), achieved <VGPR 70
- Blenrep (belantamab mafodotin) / GSK
OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1236;
P1/2
The impact of the combination on daily functioning was also minimal, as 'all' or 'most' of the time responses in OSDI ADL category were <3%.Table 1. Ocular characteristics of patients at baseline and after treatment Multiple myeloma
- talquetamab (JNJ-64407564) / J&J, Blenrep (belantamab mafodotin) / GSK, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1230;
P1, P2, P2
MonumenTAL-1 pts who met key eligibility criteria for STORM (triple-class refractory, refractory to last therapy, refractory to daratumumab, and penta- exposed) and DREAMM-2 (triple-class refractory and refractory to last therapy) were included in the analysis. These analyses show superior effectiveness of both talquetamab dosing schedules vs sel-dex and vs belamaf for most outcomes, and highlight talquetamab as a novel, highly effective treatment option for pts with TCE RRMM.
- Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
INTERIM ANALYSIS OF THE LAUNCH STUDY-A MULTICENTER, OPEN-LABEL STUDY OF SELINEXOR, DEXAMETHASONE PLUS CHEMOTHERAPY DRUGS IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1229;
P2
Once weekly selinexor and dexamethasone (Xd) combined with cyclophosphamide or liposome doxorubicin showed encouraging efficacy in relapsed/refractory MM. It also well-tolerated and no new safety signal was identified.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTR (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1227;
We failed to find difference in patients' outcome according to IPSS-WM or molecular status probably due to a lack of statistical power. More patients should be included and extensive screening of additional mutations by NGS should beperformed in our retrospective analysis to better identify subgroup who may benefit from BDR regimen.
- elranatamab (PF-06863135) / Pfizer, Darzalex (daratumumab) / J&J
ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2 (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1225;
P3
Patients should have received prior anti-myeloma therapy, including treatment with lenalidomide and a proteasome inhibitor. N/A Multiple myeloma, Clinical trial, B-cell maturation antigen, Bispecific
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP. (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1222;
No increase or new toxicities have been observed with a longer follow-up in a real-life population. KRd is also effective as bridge regimen to ASCT in patients with suboptimal response to induction therapy.
- Ninlaro (ixazomib) / Takeda
A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1221;
P2
CR and 45% of those were also flow-MRD negative <10 -5 . There was no difference in sustained MRD negativity <10 -5 or PFS between HR and NHR patients.
- inobrodib (CCS1477) / CellCentric
AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1220;
P1/2
Inobrodib is well tolerated and demonstrates promising efficacy in heavily pre-treated patients with RRMM. These results support the continued development of inobrodib in combination with standard therapies in patients with RRMM.
- Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda
REAL-WORLD TREATMENT PATTERNS IN PATIENTS INITIATING THIRD-LINE THERAPY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN GERMANY, ITALY, THE UK, FRANCE, AND SPAIN (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1219;
The 3L regimens were mostly IMiD based, and 1L and 2L regimens were R- and V-based; this was consistent with previous European studies and Tx recommendations based on clinical practice at the time of data collection. The MCR data showed changing trends from 2016-2018 to 2019-2021, with a strong shift toward triplets and anti-CD38 monoclonal antibody use in later LOTs, offering insights into recent RRMM clinical practice in Europe.
- Sarclisa (isatuximab-irfc) / Sanofi
ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1218;
The MCR data showed changing trends from 2016-2018 to 2019-2021, with a strong shift toward triplets and anti-CD38 monoclonal antibody use in later LOTs, offering insights into recent RRMM clinical practice in Europe. Pts from the treatment (triplet) and control (doublet) arms were pooled for both the ICARIA-MM (isatuximab
- Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1217;
P3
There is a statistically significant and clinically meaningful ~20 mo median PFS improvement of SVd over Vd in RRMM pts that had no prior exposure to PI and bortezomib, as well as a significant ~10 mo PFS improvement in pts with 1 prior LOT. These outcomes coupled with generally manageable AE profile emphasize the synergy between selinexor and bortezomib and the importance of a double mode of action switch, further supporting SVd use in 1) PI-na
- Blenrep (belantamab mafodotin) / GSK
BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1212;
P1/2
The frequency of meaningful decline in the pts' vision was minimal, and OAEs had only a minor impact on the pts'daily functioning. Furthermore, rapid and deep responses were observed in all cohorts, with all pts achieving ?PR.